Hormone Therapy Can Alter Blood Pressure in Transgender Individuals


Data from a pair of Washington, DC-based medical centers are providing an overview of the impact gender-affirming hormone therapy can have on blood pressure in transgender individuals.

This article was originally published on EndocrinologyNetwork.com.

Michael Irwig, MD, Director of Transgender Medicine at BIDMC

Michael Irwig, MD

Using data from the largest and longest study of its kind, a team from Beth Israel Deaconess Medical Center (BIDMC) is providing clinicians with the most comprehensive insight yet into the impact of gender-affirming hormone therapy on blood pressure in transgender individuals.

Results of the study, which included data from more than 450 patients, indicate gender-affirming hormone therapy (GAHT) was associated with blood pressure decreases among transfeminine patients but increases among transmasculine patients.

"There are many important gaps in clinicians' knowledge about the effects of hormone therapy for transgender people," said senior investigator Michael Irwig, MD, Director of Transgender Medicine at BIDMC, in a statement. "Our study sought to address these gaps by recruiting a racially and ethnically diverse pool of participants to examine the time course and magnitude of the effects of gender-affirming hormones on blood pressure."

With an interest in further understanding the potential impact of GAHT on cardiovascular risk in transgender men and women, Irwig and colleagues designed their study as a chart review to assess changes in blood pressure among patients who initiated GAHT at a pair of Washington, DC-based medical centers. Using information from the Medical Faculty Associates of The George Washington University and Whitman-Walker Health, investigators identified 470 transgender and gender-diverse adult patients for inclusion. This cohort included 247 transfeminine and 223 trans masculine patients with a mean age of 27.8 years. Investigators pointed out this cohort was made up of patients with ethnically diverse backgrounds, with non-Hispanic White patients making up less than 75% of the population.

Inclusion criteria included being 17 years of age or older, a noncisgender identity, and having data related to follow-up visits for at least 3 months for Medical Faculty Associates patients and at least 2 years for Whitman-Walker Health Patients. Investigators also noted patients were required to have baseline visits occurring between January 1, 2007 and June 1, 2015.

Among transfeminine patients, 92% were initially started on 17β-estradiol and the mean dose generally increased over time and the second most common regimen was intramuscular estradiol valerate or cypionate. Among transmasculine patients, between 77-91% were on intramuscular testosterone esters and the remainder were on transdermal formulations. Of note, a history of previous GAHT 6 months or more before the baseline visit was reported by 15% of transfeminine and 5% of trans masculine individuals.

For the purpose of analysis, blood pressure was measured at baseline and at multiple follow-up clinical visits up to 57 months after the initiation of GAHT. The outcomes of interest for the investigators’ analyses were changes to SBP and DBP following initiation of GAHT and the percentage of patients with elevated SBP (120–129 mmHg), stage 1 hypertension (SBP 130–139 mmHg or DBP 80–89 mmHg), or stage 2 hypertension (SBP at or above 140 mmHg or DBP at or above 90 mmHg) according to the 2017 American College of Cardiology and American Heart Association criteria.

Investigators found within 2-4 months of starting GAHT, mean systolic blood pressure was decreased by a mean of 4.0 mmHg in the transfeminine group (P<.0001) and increased by a mean of 2.6 mmHg in the transmasculine group (P=.02). Further analysis indicated these changes in blood pressure were maintained throughout the duration of the follow-up period. No changes in diastolic blood pressure were observed in either group.

When assessing prevalence of hypertension, investigators found the prevalence of stage 2 hypertension among transfeminine individuals decreased by 47% from 19% of individuals to 10% within 2-4 months of beginning GAHT (P=.001).

In the aforementioned statement, Irwig noted the need for further research into how race/ethnicity might play a role in modifying the risk of changes in blood pressure among transgender patients undergoing GAHT.

“Further research is needed to understand how different formulations may affect different people and to find out if there are any disparities among Black or Latinx patients,” noted Irwig.

This study, “Blood Pressure Effects of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Adults,” was published in Hypertension.

Related Videos
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Heart Failure Treatment Outcomes and Contraindications
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Video 6 - "Evaluating Safety of Novel LDL Management Mechanism"
Video 5 - "Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data"
© 2024 MJH Life Sciences

All rights reserved.